Abstract. In January 2007, Tanzania replaced sulfadoxine-pyrimethamine (SP) with artemether-lumefantrine for treatment of uncomplicated malaria. This study examined the impact of widespread SP use on molecular markers of Plasmodium falciparum drug resistance in blood samples from persons living in two villages in Korogwe District, Tanzania, from 2003 through 2007. The prevalence of the P. falciparum dihydropteroate synthase ( Pfdhps ) gene 581G mutation increased from 12% in 2003 to 56% in 2007 ( P < 0.001), resulting in an increase in the triple mutant Pfdhps haplotype SGEGA from 8% to 32% ( P < 0.001). In contrast, the chloroquine-sensitive P. falciparum chloroquine resistance transporter ( Pfcrt ) CVMNK haplotype increased from 6% to 30% ( P < 0.001). The dramatic increase of the triple Pfdhps mutant SGEGA haplotype may endanger the continued use of SP for intermittent presumptive treatment of pregnant women (IPTp). Further studies are needed to determine the importance of Pfdhps SGEGA haplotype parasites on the efficacy of SP for IPTp.
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In Tanzania, artesunate-lumefantrine (Coartem ® ; Novartis, Basel, Switzerland) was officially implemented as first-line treatment against uncomplicated malaria in January 2007, replacing sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ). The change was timely after several studies in this country during the past decade showed a rapid increase of clinical failures after SP treatment, even before SP was implemented officially in 2001. [1] [2] [3] [4] However, SP is still being used for intermittent presumptive treatment of malaria in pregnant women (IPTp) in the country. Recently, high levels of AQ resistance has also been observed. 5, 6 At molecular level, the emergence and magnitude of resistance to SP can be monitored by measuring the prevalence of single nucleotide polymorphisms (SNPs) in the P. falciparum dihydrofolate reductase ( Pfdhfr ) gene, responsible for pyrimethamine resistance 7, 8 and the dihydropteroate synthetase ( Pfdhps ) gene, responsible for sulfadoxine resistance. 9, 10 In Africa, the Pfdhfr triple mutation N51I + C59R + S108N with wild type at codons 50 (C50) and 164 (I164) are combined into the highly prevalent and resistant haplotype CIRNI. For Pfdhps , the double mutation, A437G + K540E, with wild type at codons 436 (S436), 581 (A581), and 613 (A613), are combined into the resistant haplotype SGEAA. The combination of the two haplotypes (CIRNI-SGEAA) has been associated with high-level of resistance to SP in vivo .
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Resistance to chloroquine (CQ) and AQ is mainly associated with a single K76T mutation in the P. falciparum chloroquine resistance transporter ( Pfcrt ) gene. [12] [13] [14] There are three main haplotypes in codons 72-76 of the Pfcrt gene, wild type CVMNK, and CQ-resistant haplotypes CVIET and SVMNT. 15 In Africa, the CVIET haplotype is the most dominant mutant haplotype; the SVMNT haplotype have only been observed sporadically. 16 In the light of two major policy changes in the choice of first-line antimalarial drugs in Tanzania involving CQ and SP in 2001 and 2007, the objective of the present study was to examine if changes in drug policy affected the distribution of the molecular markers of CQ, AQ, and SP resistance. Crosssectional surveys were conducted annually during [2003] [2004] [2005] [2006] [2007] in two villages with high and moderate malaria transmission intensity, respectively: Mkokola (300 meters above sea level) and Kwamasimba (600-700 meters above sea level) in Korogwe District in northeastern Tanzania. 17, 18 The villages are approximately 15 km apart.
Finger prick or venous blood samples were obtained on filter paper from all children and adolescents less than 20 years of age. DNA extraction from bloodspots and nested polymerase chain reaction (PCR), followed by sequence-specific oligonucleotide probe (SSOP)-enzyme-linked immunosorbent assay, were performed and analyzed using SSOPs targeting SNPs/ haplotypes in Pfdhfr , Pfdhps , and Pfcrt as described. 19 To confirm the presence of the c581G SNP, the PCR-restriction fragment length polymorphism method was used. With regard to the frequency of Pfdhps haplotypes, the triple mutant SGEGA haplotype increased from 8% in 2003 to 32% in 2007 ( P < 0.001). A decrease in frequency was observed for the wildtype SAKAA haplotype and the double mutant SGEAA haplotype ( Figure 1A ) .
The frequency of the triple mutant Pfdhfr CIRNI haplotype remained high at approximately 90% each year, and no major changes were observed ( Figure 1B ) . By combining the Pfdhfr and Pfdhps data, the frequency of the quintuple mutant haplotype CIRNI-SGEAA decreased significantly from 75% in 2006 to 50% in 2007 ( P = 0.014), and the sextuple mutant haplotype CIRNI-SGEGA increased in frequency from 17% to 32% ( P = 0.118). The Pfcrt mutant haplotype SVMNT was detected in both villages in 2004, 16 but was not detected in the preceding years ( Figure 1C ) . Interestingly, the wildtype haplotype CVMNK increased significantly in the study period ( P < 0.001), most markedly during 2006-2007 from 13% to 30% ( P = 0.029).
The prevalence of Pfdhps SNPs/haplotypes showed some remarkable changes during the study period ( Table 1 ) . Infections with mutants 436/437SG, 540E, and 581G increased significantly compared with pure wild types ( P < 0.001 for all comparisons). Most notably, the prevalence of 581G, including mixed 581A/G infections, increased from 11.7% to 55.6% between 2003 and 2007 ( P < 0.001). Some differences in prevalence were apparent between villages. Most notably, the prevalence of 436/437SG and 540E reached 100% in Kwamasimba in 2007. All of these infections were pure 436/437SG infections; only one infection contained 540K as a mixed 540K/E infection. For the high transmission village of Mkokola, Pfdhps wild types were still observed. Likewise, a trend for a higher prevalence of 581G in Kwamasimba (75.0%) than in Mkokola (50.0%) in 2007 was observed ( P = 0.136).
For Pfdhfr ( Table 2 ) . the prevalence of mutant genotypes 51I, 59R, and 108N was close to 100%, with minor differences in the study period. Wild type genotypes 51N, 59C, and 108S fluctuated from year to year. For Pfdhps , the prevalence of genotypes 59R and 108N reached 100% in Kwamasimba. Wild type genotypes 59C and 108S were not found in this village, but were still found in Mkokola. For Pfcrt ( Table 3 ) . the prevalence of the wild type genotype CVMNK increased significantly from 31% in 2006 to 51% in 2007 ( P = 0.021). In 2007, there was a significantly higher prevalence of CVMNK haplotype infections compared with infections without this haplotype in Mkokola (56.4%) than in Kwamasimba (33.3%), ( P = 0.021).
A steep increase in the frequency of Pfdhps SGEGA haplotypes was observed in the study period. Except for a study published in 1997 in Ifakara, Tanzania, where a prevalence of 27.8% was observed (n = 18), 21 the 581G mutation has, to our knowledge, until now been absent in Tanzania. 4, 22, 23 In addition to the present study, a recent study in the Hale, Tanga region of Tanzania detected a frequency of the 581G mutation of > 50% (Gesase S, unpublished data). Presumably, the intense use of SP in the east African region the past 5-6 years has resulted in additional accumulation of mutations conferring sulfadoxine resistance. Whether SGEGA parasites are more sulfadoxine resistant in vivo than double mutant SGEAA-parasites is unknown.
The frequency of the wild type CVMNK haplotype increased from 6% in 2003 to 30% in 2007. This finding may reflect decreasing drug pressure of 4-amino-quinolines on parasite populations in the area. Amodiaquine was discontinued as a second-line drug in January 2007. Thus, selection pressure There were noteworthy differences in prevalence of polymorphisms between the two villages. For Pfdhps and Pfdhfr , the prevalence of mutants 436/437SG and 540E in Pfdhps and 59R and 108N in Pfdhfr reached 100% in 2007 in the low transmission village of Kwamasimba. The difference in transmission intensity between the two villages may constitute the main reason for a higher frequency of SP-and CQ/ AQ-resistant mutants in Kwamasimba because a lower degree of transmission appears to favor less multi-clonality and thus a smaller reservoir of diverse drug-sensitive/resistant parasites. Because parasite prevalence decreased significantly in the study period, as in other parts of east Africa 24, 25 this finding may cause persistence of Pfdhps / Pfdhfr mutants even after SP drug pressure has ceased.
In the study area, the main source of antimalarial drugs is community resource persons, who stopped prescribing SP in February 2007. However, a continued antifolate drug pressure is persisting beyond the formal policy change because SP is still prescribed for IPTp and other sulfonamide-antifolate drugs, such as sulfamethoxazole-trimethoprim, are increasingly being used as chemoprophylaxis against opportunistic infections in person infected with human immunodeficiency virus. Further studies are needed to determine whether continued accumulation of mutations in Pfdhps may endanger the efficacy of SP for IPTp. 
